Description

Taltobulin (HTI-286), a synthetic analogue of the tripeptide hemiasterlin, is a potent antimicrotubule agent that circumvents P-glycoprotein-mediated resistance in vitro and in vivo. Taltobulin inhibits the polymerization of purified tubulin, disrupts microtubule organization in cells, and induces mitotic arrest, as well as apoptosis[1].–20°C, 3 years; 4°C, 2 years (Powder)-Applications-Cancer-programmed cell death-Formula-C27H43N3O4-Citation–References-[1]Loganzo F, et al. HTI-286, a synthetic analogue of the tripeptide hemiasterlin, is a potent antimicrotubule agent that circumvents P-glycoprotein-mediated resistance in vitro and in vivo. Cancer Res. 2003 Apr 15;63(8):1838-45.-CASNumber-228266-40-8-MolecularWeight-473.65-Compound Purity-99.90-SMILES-CC(C)(C)[C@H](NC([C@H](C(C)(C1=CC=CC=C1)C)NC)=O)C(N([C@@H](C(C)C)/C=C(C(O)=O)C)C)=O-Research_Area-Cancer-Solubility-DMSO : ≥ 100 mg/mL-Target-ADC Cytotoxin;Apoptosis;Microtubule/Tubulin-Isoform-Traditional Cytotoxic Agents-Pathway-Antibody-drug Conjugate/ADC Related;Apoptosis;Cell Cycle/DNA Damage;Cytoskeleton-MCE Product type-ADC Related